(ATNM) Actinium Pharmaceuticals, Inc. SWOT Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ATNM) Actinium Pharmaceuticals, Inc. Complete Analysis Pack
Dive Deeper Into the Research Trail Behind the Analysis
This Actinium Pharmaceuticals, Inc. SWOT Analysis gives a concise, structured view of the company’s strengths, weaknesses, opportunities, and threats—useful for investing, strategy, or research—and this page already includes a real preview of the report so you can judge format and substance. Purchase the full version to download the complete, ready-to-use analysis.
Strengths
1 lead asset in Phase III for relapsed or refractory AML
Actinium’s lead asset, I-131 apamistamab (Iomab-B), is in a pivotal Phase III trial, giving the company a late-stage program in relapsed or refractory AML. AML still causes about 11,000 U.S. deaths a year, and the disease mainly hits older adults, with a median diagnosis age near 68. Iomab-B targets elderly patients preparing for bone marrow transplant, a narrow, high-need group with few good options.
5 active collaboration tracks across oncology programs
Actinium Pharmaceuticals, Inc. has 5 active collaboration tracks across oncology, including disclosed work with Memorial Sloan Kettering Cancer Center, Astellas Pharma, EpicentRx, and AVEO Oncology. These alliances widen development reach and reduce the need for Actinium to fund each program alone. They also help validate its platform in both blood cancers and solid tumors.
3 radioisotopes in the platform toolkit
Actinium Pharmaceuticals uses Actinium-225, Iodine-131, and Lutetium-177, giving it 3 distinct radioisotope platforms. That mix supports different tumor targets and treatment designs, so the company is not tied to one modality. A broader isotope base can also lower scientific concentration risk as programs move through development.
6 validated cancer targets in development
Actinium Pharmaceuticals, Inc. has 6 validated cancer targets in development across CD45, CD33, CD38, CD47, HER2, and HER3. These markers are already clinically recognized in hematologic and solid tumors, so the pipeline is not tied to one disease path. A target-rich mix gives the Company more shots on goal and lowers single-asset risk.
- 6 targets across blood and solid tumors
- CD45, CD33, CD38, CD47, HER2, HER3
- More shots on goal, less pipeline concentration
2000-founded company with BMT focus
Actinium Pharmaceuticals, Inc. was founded in 2000 and is headquartered in New York City, giving it 25 years of operating history in targeted radiopharmaceuticals. That long run supports a clear niche in bone marrow transplant and cell therapy conditioning, where focused know-how matters. As a strengths point, this specialist focus helps the company stay concentrated on a defined clinical lane.
- Founded in 2000
- Headquartered in New York City
- Clear BMT and conditioning niche
- 25 years of domain focus
Actinium’s Late-Stage Iomab-B and Broad Pipeline Strengthen Its Case
Actinium Pharmaceuticals, Inc.’s key strength is its late-stage Iomab-B program in relapsed or refractory AML, a hard-to-treat market with about 11,000 U.S. deaths a year. Its 3 radioisotope platforms and 6 validated targets spread risk across blood and solid tumors. Five active collaborations also widen reach and lower solo funding needs.
| Strength | Data |
|---|---|
| Late-stage asset | Phase III Iomab-B |
| Platforms | 3 isotopes |
| Targets | 6 cancer targets |
| Collabs | 5 active tracks |
What is included in the product
Detailed Word Document
Provides a clear SWOT framework for analyzing Actinium Pharmaceuticals, Inc.’s business strategy
Editable Excel File
Offers a quick, clear SWOT snapshot to simplify Actinium Pharmaceuticals’ strategic analysis.
Reference Sources
Provides a concise, traceable list of primary sources (clinical trials, SEC filings, peer‑reviewed studies, and industry reports) to validate Actinium Pharmaceuticals’ key claims.
Weaknesses
0 approved products
Actinium Pharmaceuticals, Inc. still has 0 approved products, so it remains a clinical-stage company with no marketed therapy or product sales. In its latest filings, the Company reported no commercial revenue and continued to rely on cash and external financing to fund trials. That leaves value creation tied to clinical results, FDA progress, and capital markets access.
1 core late-stage asset
Actinium Pharmaceuticals, Inc.’s near-term value is still concentrated in Iomab-B, so one clinical or regulatory setback could trigger a sharp valuation reset. That concentration risk is especially hard on a single-asset biotech, where one late-stage miss can wipe out most of the pipeline premium.
High cash burn profile
Actinium Pharmaceuticals, Inc. faces a high cash burn because Phase III oncology trials can cost tens of millions of dollars, and radiopharmaceutical manufacturing adds heavy CMC and supply-chain spend. Clinical ops, site monitoring, and FDA work also drain cash fast. For a small biotech, that spending can pressure liquidity and force dilution or extra financing.
Limited commercialization infrastructure
Actinium Pharmaceuticals, Inc. still has a mostly R&D-led setup, not a mature sales force, so it would likely struggle to launch and scale a product fast after approval. In its latest filings, Actinium reported no product revenue and continued to post operating losses, which points to limited commercial buildout. It may need a partner or new spend on sales, market access, and supply chain.
- R&D first, sales later
- No revenue base yet
- Needs partner or buildout
Multiple programs still early stage
Several Actinium Pharmaceuticals, Inc. pipeline assets are still in preclinical or Phase I testing, so they are years from any possible revenue and remain exposed to high failure risk. Early-stage oncology programs often face steep attrition, so each new asset adds upside but little near-term certainty. This makes the pipeline promising, but not yet a dependable growth driver.
- Preclinical and Phase I: highest risk.
- Long timelines delay cash flow.
- Future upside, limited near-term certainty.
Actinium's weak spot: no revenue and single-asset risk
Actinium Pharmaceuticals, Inc. remains a clinical-stage Company with 0 approved products and no commercial revenue, so it still depends on cash raises to fund R&D. Its weakness is concentration risk: Iomab-B drives most of the story, so any setback can hit valuation hard. High trial and CMC spend also keep burn elevated.
| Weakness | Data point |
|---|---|
| Commercial base | 0 approved products |
| Revenue | No product sales |
| Pipeline risk | Single-asset concentration |
Preview Before You Purchase
Actinium Pharmaceuticals, Inc. Reference Sources
This is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, covering Actinium Pharmaceuticals' strengths, weaknesses, opportunities, and threats with actionable insights. Buy to unlock the complete, editable version.
Opportunities
1 large unmet need in elderly AML conditioning
AML is mainly a disease of older adults, with median age about 69, and many relapsed or refractory patients are not fit for standard transplant conditioning. Iomab-B targets this gap; in the SIERRA study, 6-month durable remission was 22% vs 0% with physician’s choice, showing a clear unmet need. If approval and access align, that could support meaningful adoption.
CAR T conditioning expansion with MSKCC
Actinium Pharmaceuticals, Inc. is extending Iomab-B beyond bone marrow transplant conditioning into CD19-targeted CAR T preparation with Memorial Sloan Kettering Cancer Center. That creates a second high-value use case in cellular therapy, not just transplant, and could broaden the addressable market if the regimen improves safety or access.
MSKCC is one of the top CAR T centers, and global CAR T sales are still growing fast, with multiple therapies already generating billions in annual revenue. If Iomab-B can make CAR T easier to deliver in frail or older patients, it could support a larger share of the roughly 40,000-plus U.S. CAR T-eligible lymphoma and leukemia patients each year.
3 isotope platform expansion paths
Actinium Pharmaceuticals, Inc. can reuse its Ac-225 alpha-particle know-how across new targets, combos, and disease areas; Ac-225 has a 10-day half-life, which supports multiple therapeutic and theranostic builds. The same isotope base can speed expansion beyond one program, with the Company already advancing multiple pipeline uses of its platform. That lowers redeployment costs and widens the shot count from one core technical engine.
2 solid-tumor partnership routes
Actinium Pharmaceuticals, Inc.’s Astellas and AVEO ties give it two solid-tumor shots beyond hematologic cancers. Solid tumors make up about 90% of adult cancers, versus Actinium Pharmaceuticals, Inc.’s current transplant niche, so even modest proof-of-concept could expand the addressable market fast. The global cancer burden was about 20 million new cases in 2022, and that scale makes the upside much larger if either route works.
- Two solid-tumor partners already in hand
- Solid tumors are the bigger market
- Proof-of-concept could widen Actinium Pharmaceuticals, Inc. growth
Multiple partnership-driven catalysts
Multiple partnership-driven catalysts can matter a lot for Actinium Pharmaceuticals, Inc., because strategic alliances can bring upfront cash, milestones, and shared development costs without full internal funding. They also cut clinical risk and can speed access to trial design, manufacturing, and regulatory know-how. For a small biotech, outside validation can itself move the stock.
- Upfront cash can fund trials
- Milestones reduce financing pressure
- Partners share development risk
- External validation can lift sentiment
Actinium’s Iomab-B Targets a Big AML Transplant Gap
Actinium Pharmaceuticals, Inc. can turn Iomab-B into a first-in-class transplant-conditioning option for frail AML patients; SIERRA showed 22% 6-month durable remission vs 0% with physician’s choice. A second shot is CAR T prep with Memorial Sloan Kettering Cancer Center, where easier conditioning could widen use in older, sicker patients.
| Opportunity | Data point |
|---|---|
| AML transplant gap | Median age 69; poor-fit patients remain underserved |
| CAR T expansion | 40,000-plus U.S. eligible lymphoma and leukemia patients |
| Platform reuse | Ac-225 half-life about 10 days |
| Partner leverage | Astellas and AVEO broaden solid-tumor reach |
Threats
Phase III failure risk on Iomab-B
Iomab-B remains Actinium Pharmaceuticals, Inc.'s biggest risk because it is still tied to pivotal Phase III readout risk. If the study shows weaker efficacy or safety than expected, the asset's value could fall sharply, and a negative result could also hurt financing and partnering leverage for a company that still depends on this lead program.
Intense competition in oncology
AML, CAR T conditioning, and radiopharmaceutical oncology all face crowded competition; the U.S. has 6 approved CAR T therapies, and AML still has dozens of active clinical programs. Bigger biopharma firms bring multibillion-dollar R&D budgets, broad pipelines, and stronger sales teams. That pressure can squeeze Actinium Pharmaceuticals, Inc.’s pricing power, slow uptake, and cap market share.
Regulatory and manufacturing complexity
Radioisotope therapies need tight production, handling, and cold-chain control, so even a small supply break can delay trials or launch. Actinium Pharmaceuticals, Inc. also faces high FDA scrutiny for novel oncology drugs, which raises the bar for CMC quality and safety data. For a small biotech, one manufacturing slip can mean months of delay.
Financing and dilution risk
Actinium Pharmaceuticals, Inc. faces financing and dilution risk because clinical-stage biotechs often need repeated capital raises before any product revenue arrives. If market sentiment weakens, Actinium may have to sell equity at lower prices or with heavier discounts, which can pressure the share price and reduce each existing holder’s ownership stake.
- Repeated fund raises are common in biotech.
- Weak markets can force cheap equity sales.
- Share issuance can dilute existing holders.
Partner and execution dependence
Actinium Pharmaceuticals, Inc. faces partner and execution risk because several programs depend on outside collaborators and shared plans. If a partner slows, reprioritizes, or walks away, clinical timelines can slip and costs can rise across the pipeline. This can hit a small developer hard, since one delayed program can affect funding, trial pace, and deal value.
- External partners can delay milestones.
- Shared plans can change fast.
- One exit can slow multiple programs.
Iomab-B’s High-Stakes Readout Faces Fierce Competition and Dilution Risk
Actinium Pharmaceuticals, Inc. faces high binary risk because Iomab-B still depends on a pivotal Phase III readout, and one miss could hurt valuation, partnering, and financing. Competition is intense: the U.S. has 6 approved CAR T therapies, while AML has dozens of active programs. Manufacturing or FDA setbacks could also delay trials and raise costs. Repeated equity raises remain a dilution risk.
| Threat | Data point |
|---|---|
| Iomab-B readout | Phase III risk |
| CAR T market | 6 U.S. approvals |
| Capital need | Ongoing dilution risk |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.